Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hy... ( CHADDS FORD Pa. Sept. 2 /- Endo...)

Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism

Date:9/2/2009

CHADDS FORD, Pa., Sept. 2 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the agency has extended its review period for its long-acting testosterone undecanoate injection for men diagnosed with hypogonadism, from Sept. 2, 2009 to Dec. 2, 2009.

While the FDA has not requested additional data, the agency has informed the company that it needs more time to complete its review of the application and finalize the risk evaluation and mitigation strategy (REMS) for this product.

"Our goal is to make this significant new treatment option available to the millions of men in the U.S. suffering from low testosterone," said David Holveck, president and chief executive officer of Endo Pharmaceuticals. "We believe our application fully supports the approval of this therapy, which will be an important step in filling a gap in testosterone therapy and improving patient care."

Endo Pharmaceuticals' long-acting testosterone undecanoate, known as Nebido(R) outside the U.S., was licensed by Bayer Schering Pharma AG, Germany to Indevus Pharmaceuticals, a company that Endo acquired earlier this year. Nebido, discovered and developed by Bayer Schering Pharma AG, Germany, has subsequently been approved in 86 countries worldwide and is available in more than 50 countries across Europe, Asia Pacific and Latin America.

About Hypogonadism

Hypogonadism, or low testosterone, is a common yet largely under-recognized and under-treated condition. An estimated 13.8 million American men have testosterone levels characterized as below normal (testosterone <300ng/dl). Yet despite this high prevalence, only about 9 percent of men with low testosterone are treate
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:

(Date:12/14/2009)... Dec. 14 Heska Corporation (Nasdaq: ... a leading provider of veterinary diagnostic and ... installation of the Company,s new DRI-CHEM® 7000 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) ,, Customers receiving ... multi-patient clinical chemistry analyzer available to the ...

(Date:12/14/2009)... Enough To Wear Pink(TM) (TETWP), the grassroots cowboy ... anniversary at the signature Tough Enough To Wear ... (Wrangler NFR) in Las Vegas. While pink is ... support of the western industry and rodeo fans ... shirts, hats, bracelets and more. ,, Through ...

(Date:12/14/2009)... common CT procedures vary widely and are higher than generally thought, ... study led by University of California, San Francisco (UCSF) ... ... 14, 2009 -- Radiation doses from common CT procedures vary widely ... for cancer, according to a new study led by University of ...

(Date:12/14/2009)... The Hemophilia Federation of America (HFA) ... involving the Teamsters Local 929 and the American ... blood system depends on skilled workers to provide ... distilled into products such as clotting factor for ... ,, The Division of Blood Services at ...

(Date:12/14/2009)... small and shouldn,t worry most users, researcher says , , ... take antidepressants may have a small but statistically significant ... not on the medications, a new study finds. , ... stressed Dr. Jordan W. Smoller, an associate professor of ... a report in the Dec. 14 issue of ...

Breaking Medicine News(10 mins):Health News:Heska Announces Installation of New Chemistry Analyzer 2 Health News:Heska Announces Installation of New Chemistry Analyzer 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5 Health News:HFA Voices Blood Safety Concerns 2 Health News:Antidepressants May Raise Women's Stroke Risk 2 Health News:Antidepressants May Raise Women's Stroke Risk 3

[0] Heska Announces Installation of New Chemistry Analyzer [0] Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary [0] Variable Doses of Radiation Raise Safety Concerns for CT Procedures [0] HFA Voices Blood Safety Concerns [0] Antidepressants May Raise Women's Stroke Risk

... women,s wombs over several assisted reproduction cycles that use ... cheaper than transferring two or more embryos at one ... series of patients who choose to have only one ... (eSET). , The authors of the Finnish study published ...

... Capture, Streamlines Health Records Documentation , ... ... Corporation , a leading developer of healthcare software solutions for ... national leader in enterprise content management and business process automation, ...

... Changes that Hold Health Care Providers Responsible when ... their products are implicated in harm to patients, ... wide contractual and legal protection that renders them ... University of Pennsylvania School of Medicine, ...

... Dealing with a difficult economy and a new ... the Managed Care Executive Group,s (MCEG) annual meeting held in ... Top Ten issues list the group produces each year. ... of strategic positives funded by the federal stimulus package that ...

... Most cervical cancers arose from strains covered by the shot, ... majority of invasive cervical cancers in New Mexico in the ... (HPV16) and HPV type 18 (HPV18), says a new study. ... HPV18-positive cancers were an average of five years younger than ...

... from human papilloma virus type 16 (HPV16) and HPV type ... cancers in New Mexico in the 1980s and 1990s, according ... issue of the Journal of the National Cancer Institute. ... HPV16- or HPV18-positive cancer was 5 years younger than that ...

Other Medicine News:Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 2 Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 3 Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 4 Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 2 Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 3 Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 4 Health News:Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors? 2 Health News:Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors? 3 Health News:Economy and New President Shape This Year's Top Ten Issues Facing Managed Care Executives 2 Health News:Economy and New President Shape This Year's Top Ten Issues Facing Managed Care Executives 3 Health News:HPV Data May Aid Vaccine's Effectiveness 2 Health News:Human papillomavirus genotype distribution in New Mexico cervical cancers 2

Single embryo transfer is the cheapest and most effective strategy for assisted reproduction iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors?Economy and New President Shape This Year's Top Ten Issues Facing Managed Care Executives HPV Data May Aid Vaccine's Effectiveness Human papillomavirus genotype distribution in New Mexico cervical cancers

(Date:12/14/2009)... Seven leading cancer physicians ... Oncology Research participated in studies ... 2009 San Antonio Breast Cancer ... the Henry B. Gonzalez Convention ... . Fifteen others presented their ...

(Date:12/14/2009)... -- The board of directors of Eli Lilly and ... dividend for the first quarter of 2010 of $0.49 ... The dividend is payable March 10, 2010 to shareholders ... ,, February 12, 2010. ,, Lilly, a leading innovation-driven ... by applying the latest research from its own worldwide ...

(Date:12/14/2009)... 14 Corgenix Medical Corporation (OTC ... marketer of diagnostic test kits, and BG ... sciences company, announced today a supply agreement ... products in enzyme-linked immunosorbent assay (ELISA) microtiter ... is seeking regulatory clearance in the United ...

[0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium [0] Lilly Declares First-Quarter 2010 Dividend [0] Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)

... Conference Call Scheduled for 9:00 AM ET ... Dendreon Corporation (Nasdaq:,DNDN) announced today that it ... Phase 3, randomized, double-blind, placebo-controlled IMPACT,(IMmunotherapy for ... trial designed to assess the safety and ...

... Bioabsorbable Stent - Also,Slated for Presentation at Symposium, ... multiple clinical trials of,the world,s first pro-healing stent, ... week at the Transcatheter Cardiovascular,Therapeutics symposium, TCT 2008, ... Ph.D., of the Academic Medical Center in,Amsterdam will ...

Other Medicine Technology:Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2 Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3 Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4 Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2 Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3

Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008

... The Plan-Neofluar 63x/1.25 Oil Ph3 ... reflected-light reflection contrast. This method ... brightfield microscopy, such as cells ... a Petri dish. Moreover, this ...

... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...

... redesigned by Nikon allowing the contrast direction ... the objective. That direction, once set, is ... 10x to 40x.,Apodized phase contrast objectives,Nikon's Apodized ... image by reducing internal reflections. The result ...

... Featuring an extra-high transmission rate, especially ... comparable to the CFI plan Achromat ... fluorescence observation and photomicrography. Because ... function as multipurpose objectives for brightfield, ...

Medicine Products:

Plan-Neofluar Antiflex Plan-Apochromat objectives CFI HMC(r) Series for Hoffman Modulation Contrast CFI Plan Fluor Series for Brightfield/Phase Contrast (DLL)

Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hy...( CHADDS FORD Pa. Sept. 2 /- Endo...),Health